Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | MZ474 | LA |
The adult patient was given with the pediatric dose; The adult patient was given with the pediatric dose; This non-serious case was reported by a other health professional via sales rep and described the occurrence of adult use of a child product in a 41-year-old male patient who received HAV (Havrix pediatric) (batch number MZ474, expiry date 24-APR-2026) for prophylaxis. On 19-SEP-2025, the patient received Havrix pediatric (left deltoid). On 19-SEP-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: The adult patient was given with the pediatric dose) and underdose (Verbatim: The adult patient was given with the pediatric dose). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK receipt date: 19-SEP-2025 The reporter stated that, adult patient was given with the pediatric dose which led to adult use of child product and underdose. The patient had no primary and complicating disease. The reporter consented to follow up.